SCHEDULE: Nantahala Capital Management Reports 3.54% Stake in Avalo Therapeutics

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 1,862,250 shares, representing 3.54% of Avalo Therapeutics, Inc.'s common stock as of June 30, 2026.

Summary

• Nantahala Capital Management, LLC, and its managing members Wilmot B. Harkey and Daniel Mack, have filed a Schedule 13G, indicating their beneficial ownership of 1,862,250 shares of Avalo Therapeutics, Inc. common stock.
• This holding represents 3.54% of the total outstanding shares as of June 30, 2026.
• The filing specifies that Nantahala has shared voting and dispositive power over these shares, while the individual members also share this power.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without significant new strategic or financial information.

Positives

• Increased institutional interest indicated by the filing.
• Clear disclosure of beneficial ownership, promoting transparency.

Negatives

• No new financial performance data or strategic initiatives are disclosed in this filing.
• The filing does not provide insight into the investment thesis or future plans for the stake.

Risks

• The filing does not explicitly mention any new risks.
• Potential for future changes in beneficial ownership could impact share price volatility.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future performance or strategy.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors acquiring a significant, but not controlling, stake in a public company. This filing indicates Nantahala Capital Management's investment in Avalo Therapeutics, a biotechnology company, which aligns with typical investment patterns in the sector.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership stakes.
• Management: Awareness of a substantial institutional investor's position.

Next Steps

• Nantahala Capital Management will continue to hold its shares in Avalo Therapeutics.
• Further filings may be required if beneficial ownership changes significantly.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Nantahala Capital Management, Avalo Therapeutics, Investment Management, Shareholder Disclosure